Uncontrolled Hyperlipidemia Patient Registry
Research type
Research Study
Full title
A Registry Study of Patients with Uncontrolled Hyperlipidemia
IRAS ID
348176
Contact name
Jorg Taubel
Contact email
Sponsor organisation
Verve Therapeutics Inc.
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
This registry study will enrol participants with uncontrolled hypercholesterolemia who either have established atherosclerotic cardiovascular disease (ASCVD) or who are at a high risk of developing ASCVD. ASCVD is caused by the build-up of cholesterol and other substances (i.e., plaque) in the walls of blood vessels, increasing the risk of myocardial infarction, ischemic stroke, and peripheral artery disease.
This study primarily aims to gain a better understanding of lipid control, lipid-lowering treatment patterns, and health outcomes among patients with uncontrolled hypercholesterolemia who have established ASCVD or who are at high risk of developing ASCVD. No treatment will be provided in this study; participants are expected to continue with their routine cardiovascular standard of care (SoC).
This registry study will rely on retrospective and prospective collection of information from a participant’s medical records of routine cardiovascular SoC, as well as assessments conducted as per the protocol. The study will take approximately 5 years for the participants to complete. It will consist of an enrolment/baseline period and a registry period with 5 annual study visits where participants will undergo a series of assessments including weight measurements, blood sampling, and participant surveys.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
24/SC/0286
Date of REC Opinion
24 Sep 2024
REC opinion
Unfavourable Opinion